CVKD 10-Q filed 2026-11-16 | Key takeaways
CVKD filed its 10-Q; the most relevant disclosure change is added Strategic review and alternatives: On October 7, 2026, the Board of Directors initiated a formal strategic process to evaluate opportunities to maximize the value of the Company and its assets, engaging Tungsten Advisors as exclusive strategic financial advisor. Potential opportunities include.
Key takeaways
Net loss narrows: Q3 2026 net loss of $1.2 million (down 54% YoY) on total operating expenses of $1.3 million versus $2.7 million in Q3 2025.
Strategic review initiated: Board retained Tungsten Advisors on October 7, 2026 to evaluate asset monetization, licensing, partnerships, or corporate transactions; no assurance of completing a transaction.
Haisco program discontinued: Sichuan Haisco Pharmaceutical confirmed discontinuation of its frunexian program in China during Q3 2026, affecting Cadrenal's licensed asset under the Haisco License Agreement.
FDA Phase 3 alignment: Type D meeting with FDA on July 28, 2026 aligned on primary endpoint protocol, placebo-controlled design, and statistical analysis plan for CAD-1005 Phase 3 registrational study in HIT patients.
Cash position: $3.1 million in cash and cash equivalents as of September 30, 2026; company states existing cash will not be sufficient to meet anticipated cash requirements for the next twelve months.
Stockholders' equity: $2.9 million as of September 30, 2026, approximately $0.4 million above the $2.5 million Nasdaq Capital Market minimum stockholders' equity requirement.
Subsequent option grant: Board approved 575,000 stock options on October 9, 2026 to officers and directors at $0.91 per share, vesting immediately.
Key metrics
Disclosure changes
- Strategic review and alternatives
On October 7, 2026, the Board of Directors initiated a formal strategic process to evaluate opportunities to maximize the value of the Company and its assets, engaging Tungsten Advisors as exclusive strategic financial advisor. Potential opportunities include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, reverse merger or other strategic transactions.
Material shift in corporate strategy from independent development to potential monetization or partnership; indicates company may not have sufficient capital to independently fund Phase 3 trials. - Haisco licensing agreement - program discontinuation
During the three months ended September 30, 2026, Haisco has confirmed the discontinuation of its frunexian program in China. The company had agreed to pay eXIthera 50% of all royalties received from the Haisco Licensing Agreement following potential future commercialization of frunexian by Haisco.
Eliminates potential future royalty stream from Haisco licensing agreement; reduces potential value of frunexian asset. - FDA Phase 3 trial alignment for CAD-1005
On August 31, 2026, company announced positive feedback from a Type D meeting with FDA held on July 28, 2026. FDA aligned on key aspects of the protocol and Statistical Analysis Plan for the Phase 3 registrational study of CAD-1005 in patients with HIT, including primary endpoint definition, placebo control design, and reduced site variability metrics.
Regulatory milestone indicating FDA agreement on trial design; CAD-1005 continues to hold FDA Orphan Drug and Fast Track designations. - Going concern disclosure
Company states existing cash and cash equivalents will not be sufficient to meet anticipated cash requirements for the next twelve months. Factors raise substantial doubt about ability to continue as a going concern for at least one year from financial statement issuance date. Company retained Tungsten Advisors to lead strategic review process.
Going concern risk remains; company needs to monetize assets or obtain additional funding to continue operations. - Rare Pediatric Disease Designation amendment
On October 22, 2026, company submitted formal amendment to FDA refining tecarfarin's proposed indication to prevention of acute myocardial infarction and luminal occlusion in pediatric patients with Chronic Kawasaki Disease-Induced Giant Coronary Artery Aneurysms (defined by a localized Z-score ≥10 or absolute internal diameter ≥8 mm). Epidemiological models project newly eligible annual target prevention pool of approximately 28 to 55 patients in the United States.
RPDD status and potential PRV eligibility affects tecarfarin's strategic and out-licensing value; failure to obtain designation could materially affect negotiating leverage with potential partners. - Nasdaq listing compliance risk
Company's stockholders' equity of $2.9 million as of September 30, 2026 is only approximately $0.4 million above the $2.5 million Nasdaq minimum. Company's MVLS is below $5 million. If Nasdaq's new $5 million MVLS requirement becomes effective and MVLS stays below threshold for 30 consecutive business days, common stock would be subject to immediate suspension and delisting. Rule currently stayed by SEC.
Nasdaq delisting risk could further limit company's ability to access capital markets and execute strategic alternatives.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow CVKD in real time
Get material earnings, filing, IR, and earnings-call alerts by email.